Novel treatment for the management of ifosfamide neurotoxicity: Rationale for the use of methylene blue

Journal of Oncology Pharmacy Practice

Volumn 6, Issue 4, 2001, Pages 153-165

  Donegan, Sarah ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84990385223     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/107815520100600404     Document Type: Article

References (63)

1. Simonian NA, Gilliam FG, Chiappa KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology. 1993; 43: 2700-2702.
2. Cameron JC. Ifosfamide neurotoxicity. A challenge for nurses, a potential nightmare for patients. Cancer Nurs. 1993; 16: 40-46.
3. Anderson NR, Taldon DS. Ifosfamide extrapyramidal neurotoxicity. Cancer. 1991; 68: 72-75.
4. Patel SR, Forman AD, Benjamin RS. High dose ifosfamide induced exacerbation of peripheral neuropathy. J Natl Cancer Inst. 1994; 86: 305-306.
5. Wollf SN, Herzig RH, Fay JW, et al. High-dose N, N, N triethylenethiophosphosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies. Semin Oncol. 1990; 17: 2-6.
6. Lind MJ, Magison JM, Cerny T, et al. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res. 1989; 49: 753-757.
7. Cerny T, Lind M, Thatcher N, et al. A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). Br J Cancer. 1989; 60: 258-266.
8. Kaijser GP, Beijnen JH, Bult A, et al. Ifosfamide metabolism and pharmacokinetics (review). Anti-cancer Res. 1994; 14: 517-532.
9. Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001; 40: 41-62.
10. Aeschlimann C, Kupfer A, Schefer H, et al. Comparative pharmacokinetics of oral and IV ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos. 1998; 26: 883-890.
11. Cerny T, Castiglione M, Brunner K. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet. 1990; 335: 175.
12. Perren TJ. Turner RC, Smith IE. Encephalopathy with rapid infusion ifosfamide/mesna. Lancet. 1987; 1: 390-391.
13. Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol. 1986; 22: 815-819.
14. Heim ME, Fiene R, Schick E, et al. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol. 1981; 100: 113-116.
15. Pratt C, Goren M, Meyer W, et al. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol. 1988; 8: 1399-1401.
16. Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematoxicity and tubular nephrotoxicity by prior cis -diamminedichloroplatinium (II) therapy. Cancer Res. 1987; 47: 1457-1460.
17. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: Response and toxicity at standard doses and high dose schedule. Semin Oncol. 1990; 17: S468-S473.
18. Hill PG, Harrop JS. Ifosfamide/mesna nomogram and serum albumin. Lancet. 1986; 2: 986.
19. Miller LJ, Eaton VE. Ifosfamide induced neurotoxicity: A case report and a review of the literature. Ann Pharmacother. 1992; 26: 183-187.
20. Curtin JP, Koonings PP, Gutierrez M, et al. Ifosfamide induced neurotoxicity. Gynaecol Oncol. 1991; 42: 193-196.
21. Watkin SW, Husband DJ, Green JA. Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Onc. 1989; 25: 1303-1310.
22. Comandone S, Liboni W, Picci P, et al. Two episodes of ifosfamide-related neurotoxicity in the same patient following different schedules and doses of the drug: A case report. Tumori. 2000; 86: 483-486.
23. Pratt CB, Green AA, Horwitz ME, et al. Central nervous toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol. 1986; 4: 1253-1261.
24. Salloum E, Flamant F, Ghosn M, et al. Irreversible encephalopathy with ifosfamide/mesna. J Clin Oncol. 1987; 5: 1303-1304.
25. Verdeguer A, Castel V, Esquembre C, et al. Fatal encephalopathy with ifosfamide/mesna. Pediatr Hematol Oncol. 1989; 6: 383-385.
26. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 3776-3778.
27. DiMaggio JR, Brown R, Vaile WF, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer. 1994; 73: 1509-1514.
28. Nelsom WE, Berhman RE, Kliegman RM, eds. Defects in metabolism of lipids: Disorders of mitochondrial fatty acid metabolism. In: Textbook of Pediatrics. 15th edn. Philadelphia: WB Saunders; 1996: 360-363.
29. Kupfer A, Aeschlimann C, Wermuth B, et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet. 1994; 343: 763-764.
30. Kupfer A, Aeschlimann C, Wermuth B, et al. Experimental glutaric aciduria in rats: A new animal model for mitochondrial ifosfamide toxicity in man. Experientia. 1996; 52: 85.
31. Sweetman L, Nynan WL, Trauner DA. Glutaric aciduria type II. J Pediatr. 1980; 96: 1020-1026.
32. Goodman SJ, Stene DO, McCabe ER, et al. Glutaric acidemia type: II. Chemical, biochemical and morphological considerations. J Pediatr. 1982; 100: 946-950.
33. Sherratt HS. Hypoglycin, the famous toxin of the unripe Jamaican ackee fruit. TIPS. 1986; 186-191.
34. Goren MP, Wright RK, Pratt CB, et al. Dechloroethylation of ifosfamide and neurotoxicity. Lancet. 1986; 2: 1219-1220.
35. Wainer IW, Ducharme J, Granvil CP, et al. Ifosfamide stereoselective dichloroethylation and neurotoxicity. Lancet. 1994; 343: 982-983.
36. Brain, EG, Yu LJ, Gustaffson K, et al. Modulation of p450 dependant ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br J Cancer. 1998; 7: 1768-1776.
37. Ghosn M, Carde P, Leclerq B, et al. Ifosfamide/mesna related encephalopathy: A case report of a possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer. 1988; 75: 391-392.
38. Furusawa S, Fujimura T, Sasaki K, Takayanagi Y. Potentiation of ifosfamide toxicity by chlordiazopoxide, diazepam and oxazepam. Chem Pharm Bull. 1989; 37: 3420-3422.
39. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol. 1993; 33: 36-42.
40. Kupfer A, Aeschlimann C, Cerry T. Methylene blue and the neurotoxic mechanisms of ifosfamide neurotoxicity. Eur J Clin Pharmacol. 1996; 24: 249-252.
41. Pecci L, Montefoschi G, Fontana M, et al. Aminoethylcysteine ketamine decarboxylated dimer inhibits mitochondrial respiration by impairing electron transfer at complex I level. Biochem Biophys Acta. 1994; 748: 40-47.
42. Sood C, O’Brien PJ. 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Br J Cancer. 1996; 74: S287-S293.
43. Lind MJ, McGown AT, Hadfield JA, et al. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol. 1989; 11: 1835-1840.
44. Bhardwaj A, Badesha PS. Ifosfamide-induced nonconvulsive status epilepticus. Ann Pharmacol. 1995; 29: 1237-1239.
45. Carlson L, Goren MP, Bush DA, et al. Toxicity, pharmacokinetics and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms’ tumor. Cancer Chemother Pharmacol. 1998; 41: 140-146.
46. Schlenzig J, Charpentier C, Rabier D, et al. L -carnitine: A way to decrease cellular toxicity of ifosfamide. Eur J Pediatr. 1995; 154: 686-687.
47. McVay JI, Morgan-Wood A. Suspected ifosfamide-inducedneurotoxicity. Pharmacotherapy. 1999; 19: 1450-1455.
48. Beasley D, McGuiggin M. Interleukin-1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J Exp Med. 1994; 179: 71-80.
49. Kock HJ. Effects of methylene blue in septic shock. J Crit Care. 1996; 24: 1093-1094.
50. Greenberg SR, Kerr JH. Methylene blue in alcohol-induced hypoglycemia. Lancet. 1965; 2: 132.
51. Narsapur SL, Naylor GJ. Methylene blue: A possible treatment for depressive psychoses. J Affect Disord. 1983; 5: 155-161.
52. Naylor GJ, Smith AH, Connely P. Methylene blue in mania. Biol Psychiatry. 1988; 24: 941-942.
53. Madison LL, Locher A, Wulff J. Ethanol induces hypoglycemia. Mechanism of suppression of hepatic gluconeogenesis. Diabetes. 1967; 16: 252-258.
54. Aeschilmann C, Cerny T, Kupfer A. Inhibition of [mono] amine activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Distrib. 1996; 24: 1336-1339.
55. Lisariu T, Lauterberg BH. Long chain fatty acid oxidation in mitochondria is inhibited by chloroacetaldehyde and restored by methylene blue. Experientia. 1996; 52: 84.
56. Salaris SC, Barbs CE, Voohees WD. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. Biochem Pharmacol. 1991; 42: 499-506.
57. Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000; 56: 247-250.
58. Harpy JP, Charpentier C, Coude M. Methylene blue for riboflavin-unresponsive glutaric aciduria type II. Lancet. 1986; 1: 391.
59. Ferrero JM, Eftekari P, Largillier R, et al. Traitement d’une encephalopathie al ifosfamide par le blue methylene. Bull Cancer. 1995; 82: 392-598.
60. Alonso JL, Nieto Y, Lopez JA. Ifosfamide encephalopathy and methylene blue: A case report. Ann Oncol. 1996; 7: 643-644.
61. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide associated encephalopathy. N Engl J Med. 1995; 332: 1239-1240.
62. Serve H, Hilgenfeld E, Maurer J, et al. Use of methylene blue and bicarbonate in ifosfamide-related CNS toxicity: Case report (A1248). Eur J Cancer. 1995; 31A: S260-S261.
63. Pelgrims J. De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000; 82(2):291-294.